HCMT
GSK icon

Highland Capital Management (Tennessee)’s GSK GSK Stock Holding History

Highland Capital Management (Tennessee)’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$872K Buy
16,642
+50
+0.3% +$2.64K 0.04% 248
2026
Q1 		$916K Sell
16,592
-50
-0.3% -$2.71K 0.05% 244
2025
Q4 		$816K Sell
16,642
-2,300
-12% -$107K 0.04% 247
2025
Q3 		$818K Buy
18,942
+1,600
+9% +$62.5K 0.04% 261
2025
Q2 		$666K Sell
17,342
-1,262
-7% -$48.2K 0.04% 259
2025
Q1 		$721K Sell
18,604
-1,068
-5% -$39.1K 0.04% 254
2024
Q4 		$665K Sell
19,672
-828
-4% -$29.8K 0.04% 248
2024
Q3 		$838K Sell
20,500
-204
-1% -$8.35K 0.05% 243
2024
Q2 		$797K Sell
20,704
-1,474
-7% -$62K 0.05% 238
2024
Q1 		$951K Buy
22,178
+36
+0.2% +$1.49K 0.05% 237
2023
Q4 		$821K Sell
22,142
-100
-0.4% -$3.59K 0.05% 248
2023
Q3 		$806K Sell
22,242
-50
-0.2% -$1.77K 0.06% 246
2023
Q2 		$794K Buy
+22,292
New +$800K 0.05% 243
2023
Q1 		– Sell
-20,647
Closed -$726K – 286
2022
Q4 		$726K Buy
20,647
+100
+0.5% +$3.33K 0.05% 253
2022
Q3 		$605K Sell
20,547
-1,855
-8% -$70.3K 0.05% 243
2022
Q2 		$1.22M Hold
22,402
– – 0.09% 211
2022
Q1 		$1.22M Buy
22,402
+80
+0.4% +$4.34K 0.07% 219
2021
Q4 		$1.23M Sell
22,322
-40,652
-65% -$2.11M 0.07% 229
2021
Q3 		$3.01M Sell
62,974
-1,520
-2% -$76.3K 0.18% 146
2021
Q2 		$3.21M Sell
64,494
-320
-0.5% -$15.4K 0.19% 136
2021
Q1 		$2.89M Sell
64,814
-1,008
-2% -$45.8K 0.18% 146
2020
Q4 		$3.03M Buy
65,822
+2,364
+4% +$109K 0.19% 132
2020
Q3 		$2.99M Sell
63,458
-296
-0.5% -$14.8K 0.21% 124
2020
Q2 		$3.25M Sell
63,754
-1,188
-2% -$60.9K 0.25% 110
2020
Q1 		$3.08M Buy
64,942
+3,640
+6% +$194K 0.29% 102
2019
Q4 		$3.6M Sell
61,302
-800
-1% -$44.5K 0.25% 113
2019
Q3 		$3.31M Sell
62,102
-1,080
-2% -$55.6K 0.25% 110
2019
Q2 		$3.16M Sell
63,182
-1,272
-2% -$63.8K 0.24% 114
2019
Q1 		$3.37M Buy
64,454
+2,480
+4% +$124K 0.26% 117
2018
Q4 		$2.96M Hold
61,974
– – 0.25% 114
2018
Q3 		$3.11M Buy
61,974
+160
+0.3% +$8.13K 0.22% 122
2018
Q2 		$3.12M Sell
61,814
-184
-0.3% -$9.27K 0.24% 123
2018
Q1 		$3.03M Sell
61,998
-2,608
-4% -$121K 0.24% 117
2017
Q4 		$2.86M Sell
64,606
-1,496
-2% -$69.1K 0.22% 122
2017
Q3 		$3.35M Sell
66,102
-2,265
-3% -$115K 0.27% 114
2017
Q2 		$3.69M Buy
68,367
+4,968
+8% +$265K 0.3% 106
2017
Q1 		$3.34M Buy
63,399
+7,616
+14% +$386K 0.28% 105
2016
Q4 		$2.69M Sell
55,783
-2,079
-4% -$103K 0.23% 115
2016
Q3 		$3.12M Sell
57,862
-4,880
-8% -$268K 0.26% 111
2016
Q2 		$3.4M Sell
62,742
-2,856
-4% -$150K 0.29% 104
2016
Q1 		$3.33M Sell
65,598
-22,469
-26% -$1.12M 0.28% 108
2015
Q4 		$4.44M Buy
88,067
+42,973
+95% +$2.19M 0.36% 88
2015
Q3 		$2.17M Sell
45,094
-2,620
-5% -$136K 0.18% 157
2015
Q2 		$2.48M Buy
+47,714
New +$2.69M 0.19% 156

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Highland Capital Management (Tennessee)'s GSK Position: Q2 2026 in Review

Highland Capital Management (Tennessee) increased its GSK (GSK) stake by 0.3% in Q2 2026, buying an estimated $2.64K and bringing the position to 16,642 shares worth $872K. The position accounts for 0.04% of the portfolio, ranked #248.

Highland Capital Management (Tennessee) first reported a position in GSK in Q2 2015 and has held it in 44 quarters since. The position peaked at $4.44M in Q4 2015. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Highland Capital Management (Tennessee) held 16,642 shares of GSK worth $872K as of Q2 2026.
  • Highland Capital Management (Tennessee) bought 50 GSK shares in Q2 2026, an estimated $2.64K.
  • GSK made up 0.04% of Highland Capital Management (Tennessee)'s portfolio in Q2 2026, its #248 holding.
  • Highland Capital Management (Tennessee) first reported a position in GSK in Q2 2015 and has held it in 44 quarters since.
  • Highland Capital Management (Tennessee)'s GSK position peaked at $4.44M in Q4 2015.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Highland Capital Management (Tennessee)'s 13F filing for Q2 2026, filed 21 Jul 2026.